Statistik Asas
| LEI | 549300T5URIXWDILX594 |
| CIK | 1029142 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Dynavax Technologies Corporation
SEC Filings (Chronological Order)
Halaman ini menyediakan senarai kronologi lengkap bagi Pemfailan SEC, tidak termasuk pemfailan pemilikan yang kami sediakan di tempat lain.
| August 21, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 21, 2025 Dynavax Technologies Corporation (Exact name of Registrant as Specified in Its Charter) Delaware 001-34207 33-0728374 (State or Other Jurisdiction of Incorporation) (C |
|
| August 21, 2025 |
EX-99.2 Corporate Presentation Using Proven, Innovative Adjuvant Technology to Help Protect the World Against Infectious Diseases August 2025 Nasdaq: DVAX Exhibit 99.2 Statements contained in this presentation regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements about Dynava |
|
| August 21, 2025 |
EX-99.1 Exhibit 99.1 Dynavax Announces Positive Topline Phase 1/2 Results Supporting Potential Best-in-Class Shingles Vaccine Profile • At all doses and formulations evaluated in Part 1 of the trial, Z-1018 was well-tolerated and demonstrated a favorable tolerability profile, including lower solicited local and systemic post-injection reactions, versus Shingrix • Z-1018 demonstrated robust immune |
|
| August 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 7, 2025 Dynavax Technologies Corporation (Exact name of Registrant as Specified in Its Charter) Delaware 001-34207 33-0728374 (State or Other Jurisdiction of Incorporation) (Co |
|
| August 7, 2025 |
Dynavax Reports Second Quarter 2025 Financial Results Exhibit 99.1 Dynavax Reports Second Quarter 2025 Financial Results •Record HEPLISAV-B® quarterly net product revenue of $92 million, representing 31% year-over-year growth •Refines full year 2025 HEPLISAV-B net product revenue guidance range to $315 to $325 million, from $305 to $325 million •Top-line results in Part 1 of Phase 1/2 shingles vaccine trial expected in August 2025 •Completed dosing i |
|
| August 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 00 |
|
| June 17, 2025 |
Restated Certificate of Incorporation Exhibit 3.1 RESTATED CERTIFICATE OF INCORPORATION OF DYNAVAX TECHNOLOGIES CORPORATION Dynavax Technologies Corporation, a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the “Corporation”) DOES HEREBY CERTIFY: FIRST: The name of the Corporation is Dynavax Technologies Corporation. The Corporation was originally incorporated under the |
|
| June 17, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 11, 2025 Dynavax Technologies Corporation (Exact name of Registrant as Specified in Its Charter) Delaware 001-34207 33-0728374 (State or Other Jurisdiction of Incorporation) (Com |
|
| June 17, 2025 |
Exhibit 3.2 AMENDED AND RESTATED BYLAWS OF DYNAVAX TECHNOLOGIES CORPORATION (A DELAWARE CORPORATION) AMENDED AND RESTATED BYLAWS OF DYNAVAX TECHNOLOGIES CORPORATION (A DELAWARE CORPORATION) ARTICLE I OFFICES Section 1. Registered Office. The registered office of the corporation in the State of Delaware shall be in the City of Wilmington, County of New Castle. Section 2. Other Offices. The corporat |
|
| June 9, 2025 |
DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Pro |
|
| June 9, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A (Rule 14A-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☐ Filed by a Party other than the Registrant ☒ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Ru |
|
| June 6, 2025 |
DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Pro |
|
| June 5, 2025 |
DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Pro |
|
| June 4, 2025 |
DFAN14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A (Rule 14A-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☐ Filed by a Party other than the Registrant ☒ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitt |
|
| June 4, 2025 |
DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Pro |
|
| May 27, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A (Rule 14A-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☐ Filed by a Party other than the Registrant ☒ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Ru |
|
| May 23, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State |
|
| May 19, 2025 |
DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Pro |
|
| May 19, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A (Rule 14A-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☐ Filed by a Party other than the Registrant ☒ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Ru |
|
| May 16, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A (Rule 14A-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☐ Filed by a Party other than the Registrant ☒ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Ru |
|
| May 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 8, 2025 Dynavax Technologies Corporation (Exact name of Registrant as Specified in Its Charter) Delaware 001-34207 33-0728374 (State or Other Jurisdiction of Incorporation) (Commi |
|
| May 12, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State |
|
| May 12, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) o Definitive Proxy State |
|
| May 12, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) o Definitive Proxy State |
|
| May 12, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A (Rule 14A-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☐ Filed by a Party other than the Registrant ☒ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Ru |
|
| May 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State |
|
| May 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State |
|
| May 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 0 |
|
| May 6, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 6, 2025 Dynavax Technologies Corporation (Exact name of Registrant as Specified in Its Charter) Delaware 001-34207 33-0728374 (State or Other Jurisdiction of Incorporation) (Commi |
|
| May 6, 2025 |
DFAN14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A (Rule 14A-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☐ Filed by a Party other than the Registrant ☒ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitt |
|
| May 6, 2025 |
Dynavax Reports First Quarter 2025 Financial Results and Announces New Pipeline Programs Exhibit 99.1 Dynavax Reports First Quarter 2025 Financial Results and Announces New Pipeline Programs •Record HEPLISAV-B® first quarter net product revenue of $65 million, representing 36% year-over-year growth •Top-line results in Part 1 of Phase 1/2 shingles vaccine trial expected in Q3 2025 •New pandemic influenza adjuvant program and Lyme disease vaccine programs planned to enter clinical deve |
|
| April 29, 2025 |
DEFA14A 1 c112602def14a.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)( |
|
| April 22, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A (Rule 14A-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☐ Filed by a Party other than the Registrant ☒ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Ru |
|
| April 21, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☐ Filed by a Party other than the Registrant ☒ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of |
|
| April 17, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e) |
|
| April 17, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State |
|
| April 17, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. 1) Filed by the Registrant ☐ Filed by a Party other than the Registrant ☒ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confid |
|
| April 16, 2025 |
DFAN14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A (Rule 14A-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☐ Filed by a Party other than the Registrant ☒ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitt |
|
| April 15, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. 1) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e |
|
| April 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☐ Filed by a Party other than the Registrant ☒ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of |
|
| April 4, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) o Definitive Proxy State |
|
| April 3, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: x Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e) |
|
| March 13, 2025 |
Exhibit 4.1 DYNAVAX TECHNOLOGIES CORPORATION AND U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION, as Trustee INDENTURE Dated as of March 13, 2025 2.00% Convertible Senior Notes due 2030 TABLE OF CONTENTS PAGE ARTICLE 1 DEFINITIONS Section 1.01. Definitions 1 Section 1.02. References to Interest 15 ARTICLE 2 ISSUE, DESCRIPTION, EXECUTION, REGISTRATION AND EXCHANGE OF NOTES Section 2.01. Designation a |
|
| March 13, 2025 |
Entry into a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 13, 2025 Dynavax Technologies Corporation (Exact name of Registrant as Specified in Its Charter) Delaware 001-34207 33-0728374 (State or Other Jurisdiction of Incorporation) (Co |
|
| March 10, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A (Rule 14A-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☐ Filed by a Party other than the Registrant ☒ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Ru |
|
| March 6, 2025 |
Entry into a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 5, 2025 Dynavax Technologies Corporation (Exact name of Registrant as Specified in Its Charter) Delaware 001-34207 33-0728374 (State or Other Jurisdiction of Incorporation) (Com |
|
| March 6, 2025 |
Form of Exchange and Subscription Agreement Exhibit 10.1 March 5, 2025 Dynavax Technologies Corporation 2100 Powell Street, Suite 720 Emeryville, California 94608 Attention: Chief Financial Officer Re: Exchange and/or Subscription for Dynavax Technologies Corporation Convertible Senior Notes due 2030 Ladies and Gentlemen: Dynavax Technologies Corporation, a Delaware corporation, (the “Company”), is offering a new series of its Convertible S |
|
| February 20, 2025 |
Exhibit 10.24 6. Addendum to the rental agreement dated December 27, 2006 (No. 9.2077.11.03) with 1st addendum from July 1st / 5th, 2019 2. Addendum from July 30th / August 11th, 2020 3. Addendum from November 11th / December 3rd, 2020 4. Addendum from September 13, 2021 and 5th addendum dated February 7, 2023 Object: Eichsfelder Straße 1-11, 40595 Düsseldorf between Onyx Düsseldorf S.à r.l. 2-4, |
|
| February 20, 2025 |
EXHIBIT 10.7 AMENDMENT NO. 1 TO CONSULTING AGREEMENT AND STATEMENT OF WORK NO. 1 This Amendment No. 1, effective as of January 16, 2025 (the "Amendment No. 1 Effective Date") (“Amendment No. 1”) amends that certain Consulting Agreement and Statement of Work No. 1 having an effective date of January 16, 2023 by and between the parties hereto (each a "Party" and collectively the "Parties")(the “Agre |
|
| February 20, 2025 |
Exhibit 4.1 DESCRIPTION OF CAPITAL STOCK References herein to “Dynavax,” “our,” “we,” “us” and the “Company” refer only to Dynavax Technologies Corporation. General Our authorized capital stock consists of 278,000,000 shares of common stock, $0.001 par value per share, and 5,000,000 shares of preferred stock, $0.001 par value per share, 300,000 of which has been designated Series A Junior Particip |
|
| February 20, 2025 |
First Amendment to Lease, dated December 2, 2024, by and between Company and SPUS8 2100 Powell, L.P. Exhibit 10.26 FIRST AMENDMENT TO LEASE (Dynavax Technologies Corporation – 2100 Powell) THIS FIRST AMENDMENT TO LEASE (“Amendment”) is dated effective and for identification purposes as of December 2, 2024 (the "Effective Date"), and is made by and between SPUS8 2100 POWELL, LP, a Delaware limited partnership (“Landlord”), and DYNAVAX TECHNOLOGIES CORPORATION, a Delaware corporation (“Tenant”). RE |
|
| February 20, 2025 |
Non-Employee Director Compensation Policy Exhibit 10.11 DYNAVAX TECHNOLOGIES CORPORATION NON-EMPLOYEE DIRECTOR COMPENSATION POLICY EFFECTIVE JANUARY 2025 Directors who are not Employees (“Non-Employee Directors”) shall receive equity and cash compensation as set forth below. Capitalized terms used in this Policy, unless otherwise defined herein, have the meaning given to them in the Company’s Amended and Restated 2018 Equity Incentive Pla |
|
| February 20, 2025 |
Offer Letter, dated May 26, 2021, by and between Company and John Slebir Exhibit 10.5 May 26, 2021 John Slebir [address] Subject: Revised Offer Letter Dear John: Dynavax Technologies is pleased to offer you the position of Senior Vice President and General Counsel, on the terms outlined below. We are excited that you will be joining our team of dedicated and talented professionals focused on investigating, developing, and commercializing innovative vaccines to provide |
|
| February 20, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-34207 |
|
| February 20, 2025 |
, between Company and West Pharmaceutical Services, Inc. EXHIBIT 10.30 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND REPLACED WITH “[***]”. SUCH IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT CUSTOMARILY AND ACTUALLY TREATS AS PRIVATE OR CONFIDENTIAL. SUPPLY AGREEMENT THIS SUPPLY AGREEMENT (this “Agreement”) dated January 1, 2025 (the “Effective Dat |
|
| February 20, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 19, 2025 Dynavax Technologies Corporation (Exact name of Registrant as Specified in Its Charter) Delaware 001-34207 33-0728374 (State or Other Jurisdiction of Incorporation) |
|
| February 20, 2025 |
EXHIBIT 10.29 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND REPLACED WITH “[***]”. SUCH IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT CUSTOMARILY AND ACTUALLY TREATS AS PRIVATE OR CONFIDENTIAL. SECOND AMENDMENT TO COMMERCIAL MANUFACTURING AND SUPPLY AGREEMENT This Second Amendment to Commerci |
|
| February 20, 2025 |
Exhibit 19.1 Dynavax Technologies Corporation Insider Trading Policy (Adopted May 25, 2023) Introduction During the course of your relationship with Dynavax Technologies Corporation (“Dynavax”), you may receive material information that is not yet publicly available (“material nonpublic information”) about Dynavax or other publicly traded companies that Dynavax has business relationships with. Mat |
|
| February 20, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 20, 2025 Dynavax Technologies Corporation (Exact name of Registrant as Specified in Its Charter) Delaware 001-34207 33-0728374 (State or Other Jurisdiction of Incorporation) |
|
| February 20, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 19, 2025 Dynavax Technologies Corporation (Exact name of Registrant as Specified in Its Charter) Delaware 001-34207 33-0728374 (State or Other Jurisdiction of Incorporation) |
|
| February 20, 2025 |
Exhibit 99.1 Dynavax Responds to Deep Track and Highlights Long-Term Value Creation Strategy Reiterates Meaningful Board Change Already Underway EMERYVILLE, Calif., Feb. 19, 2025 – Dynavax Technologies Corporation (Nasdaq: DVAX) (“Dynavax” or the “Company”), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today issued a statement underscoring contin |
|
| February 20, 2025 |
Exhibit 21.1 List of Subsidiaries Dynavax GmbH Dynavax India LLP |
|
| February 20, 2025 |
Exhibit 99.1 Dynavax Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Full Year 2025 Financial Guidance •HEPLISAV-B® 2024 net product revenue grew 26% year-over-year to $268 million; net product revenue expected to be $305 to $325 million in 2025 •Top-line results in Phase 1/2 shingles trial expected in Q3 2025 •Plan to initiate Phase 2 trial for plague vaccine in Q3 2025 • |
|
| February 19, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A (Rule 14A-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☐ Filed by a Party other than the Registrant ☒ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Ru |
|
| February 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 10, 2025 Dynavax Technologies Corporation (Exact name of Registrant as Specified in Its Charter) Delaware 001-34207 33-0728374 (State or Other Jurisdiction of Incorporation) |
|
| February 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 3, 2025 Dynavax Technologies Corporation (Exact name of Registrant as Specified in Its Charter) Delaware 001-34207 33-0728374 (State or Other Jurisdiction of Incorporation) ( |
|
| January 29, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 26, 2025 Dynavax Technologies Corporation (Exact name of Registrant as Specified in Its Charter) Delaware 001-34207 33-0728374 (State or Other Jurisdiction of Incorporation) ( |
|
| January 13, 2025 |
Dynavax Announces Preliminary Unaudited Fourth Quarter and Full Year 2024 Financial Highlights Exhibit 99.1 Dynavax Announces Preliminary Unaudited Fourth Quarter and Full Year 2024 Financial Highlights •Preliminary 2024 HEPLISAV-B® net product revenue grew 26% year-over-year to approximately $268 million •Enrollment completed in Phase 1/2 shingles trial; top line results expected in Q3 2025 •New $30 million contract with U.S. Department of Defense to advance plague vaccine program •Cash, c |
|
| January 13, 2025 |
Corporate Presentation Using Proven, Innovative Adjuvant Technology to Help Protect the World Against Infectious Diseases January 2025 Nasdaq: DVAX Forward-Looking Statements Statements contained in this presentation regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements about |
|
| January 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 13, 2025 Dynavax Technologies Corporation (Exact name of Registrant as Specified in Its Charter) Delaware 001-34207 33-0728374 (State or Other Jurisdiction of Incorporation) ( |
|
| December 27, 2024 |
Exhibit 4.1 AMENDMENT NO. 1 TO RIGHTS AGREEMENT This Amendment No. 1 to the Rights Agreement (this “Amendment”) is made and entered into as of December 26, 2024, by and between Dynavax Technologies Corporation, a Delaware corporation (the “Company”), and Computershare Trust Company, N.A., a federally chartered trust company, as rights agent (the “Rights Agent”), and amends that certain Rights Agre |
|
| December 27, 2024 |
Entry into a Material Definitive Agreement, Material Modification to Rights of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 26, 2024 Dynavax Technologies Corporation (Exact name of Registrant as Specified in Its Charter) Delaware 001-34207 33-0728374 (State or Other Jurisdiction of Incorporation) |
|
| November 14, 2024 |
SC 13G 1 dvax111424.htm KYNAM CAPITAL MANAGEMENT, LP UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Dynavax Technologies Corp. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 268158201 (CUSIP Number) September 30, 2024 (Date of Event which Requires Filing of this Statement) Chec |
|
| November 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 8, 2024 Dynavax Technologies Corporation (Exact name of Registrant as Specified in Its Charter) Delaware 001-34207 33-0728374 (State or Other Jurisdiction of Incorporation) ( |
|
| November 7, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 7, 2024 Dynavax Technologies Corporation (Exact name of Registrant as Specified in Its Charter) Delaware 001-34207 33-0728374 (State or Other Jurisdiction of Incorporation) ( |
|
| November 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file numbe |
|
| November 7, 2024 |
Dynavax Reports Third Quarter 2024 Financial Results and Provides Business Updates Exhibit 99.1 Dynavax Reports Third Quarter 2024 Financial Results and Provides Business Updates •HEPLISAV-B® quarterly net product revenue of $79.3 million, representing 27% year-over-year growth •Hepatitis B adult vaccine market expected to expand to a peak of over $900 million by 2030, with HEPLISAV-B expected to achieve at least 60% estimated total market share •Expect positive net income in 20 |
|
| October 29, 2024 |
Dynavax Adopts Limited-Duration Stockholder Rights Plan Exhibit 99.1 Dynavax Adopts Limited-Duration Stockholder Rights Plan EMERYVILLE, CA – October 29, 2024 – Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today announced that its Board of Directors has adopted a limited-duration stockholder rights plan, effective immediately (the “Rights Plan”). The Dy |
|
| October 29, 2024 |
Exhibit 3.1 AMENDED AND RESTATED CERTIFICATE OF DESIGNATION OF RIGHTS, PREFERENCES AND PRIVILEGES OF SERIES A JUNIOR PARTICIPATING PREFERRED STOCK OF DYNAVAX TECHNOLOGIES CORPORATION The undersigned, Kelly MacDonald, does hereby certify: 1. That she is duly elected and acting Chief Financial Officer of DYNAVAX TECHNOLOGIES CORPORATION, a Delaware corporation (the “Corporation”). 2. That pursuant |
|
| October 29, 2024 |
Exhibit 4.1 RIGHTS AGREEMENT Dated as of October 28, 2024 TABLE OF CONTENTS Page SECTION 1. CERTAIN DEFINITIONS 1 SECTION 2. APPOINTMENT OF RIGHTS AGENT 10 SECTION 3. ISSUANCE OF RIGHTS 10 SECTION 4. FORM OF RIGHT CERTIFICATES 12 SECTION 5. COUNTERSIGNATURE AND REGISTRATION 13 SECTION 6. TRANSFER, SPLIT UP, COMBINATION AND EXCHANGE OF RIGHT CERTIFICATES; MUTILATED, DESTROYED, LOST OR STOLEN RIGHT |
|
| October 29, 2024 |
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 DYNAVAX TECHNOLOGIES CORPORATION (Exact Name of Registrant as Specified in its Charter) Delaware 33-0728374 (State of Incorporation or Organization) (I. |
|
| October 29, 2024 |
Regulation FD Disclosure, Entry into a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 28, 2024 Dynavax Technologies Corporation (Exact name of Registrant as Specified in Its Charter) Delaware 001-34207 33-0728374 (State or Other Jurisdiction of Incorporation) ( |
|
| October 24, 2024 |
EX-99.3 2 d901674dex993.htm EX-99.3 Exhibit 99.3 TRADING DATA The following table sets forth all transactions with respect to shares of Common Stock effected on behalf of the Reporting Persons since the filing of the Schedule 13D on September 16, 2024 in respect of the shares of Common Stock, inclusive of any transactions effected prior to the filing hereof. Except as otherwise indicated, all such |
|
| October 24, 2024 |
DVAX / Dynavax Technologies Corporation / Deep Track Capital, LP - SC 13D/A Activist Investment SC 13D/A 1 d901674dsc13da.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Amendment No. 1)* (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2(a) Under the Securities Exchange Act of 1934 Dynavax Technologies Corporation (Name of Issuer) Common Stock, par va |
|
| October 16, 2024 |
DVAX / Dynavax Technologies Corporation / STATE STREET CORP Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* DYNAVAX TECHNOLOGIES CORP (Name of Issuer) COMMON STOCK (Title of Class of Securities) 268158201 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is |
|
| September 16, 2024 |
DVAX / Dynavax Technologies Corporation / Deep Track Capital, LP - SC 13D Activist Investment SC 13D 1 d888084dsc13d.htm SC 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 Dynavax Technologies Corporation (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 268158201 (CUSIP Number) David Kroin Deep Track Capital, LP 200 Greenwich Ave, 3rd Floor Greenwich, CT 06830 (203) 40 |
|
| September 16, 2024 |
EX-99.2 3 d888084dex992.htm EX-99.2 Exhibit 99.2 TRADING DATA The following table sets forth all transactions with respect to shares of Common Stock effected in the last sixty days by the Reporting Persons on behalf of the Reporting Persons in respect of the shares of Common Stock, inclusive of any transactions effected prior to the filing hereof. Except as otherwise indicated, all such transactio |
|
| September 16, 2024 |
AGREEMENT JOINT FILING OF SCHEDULE 13D EX-99.1 2 d888084dex991.htm EX-99.1 Exhibit 99.1 AGREEMENT JOINT FILING OF SCHEDULE 13D The undersigned hereby agree to jointly prepare and file with regulatory authorities this Schedule 13D and any future amendments thereto reporting each of the undersigned’s ownership of securities of Dynavax Technologies Corporation, and hereby affirm that such Schedule 13D is being filed on behalf of each of t |
|
| September 9, 2024 |
DVAX / Dynavax Technologies Corporation / FEDERATED HERMES, INC. Passive Investment OMB APPROVAL OMB Number: 3235-0145 Estimated average burden hours per response ….11 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 24*) DYNAVAX TECHNOLOGIES CORPORATION (Name of Issuer) COMMON STOCK (Title of Class of Securities) 268158201 (CUSIP Number) August 31, 2024 (Date of Event Which Requires Fili |
|
| August 6, 2024 |
Dynavax Technologies Corporation 2018 Equity Incentive Plan Exhibit 10.1 Dynavax Technologies Corporation 2018 Equity Incentive Plan Adopted by the Board of Directors: April 8, 2018 Approved by the Stockholders: May 31, 2018 Amended and Restated by the Board of Directors: April 9, 2019 Approved by the Stockholders: May 30, 2019 Amended and Restated by the Board of Directors: April 3, 2020 Approved by the Stockholders: May 28, 2020 Amended and Restated by t |
|
| August 6, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 06, 2024 Dynavax Technologies Corporation (Exact name of Registrant as Specified in Its Charter) Delaware 001-34207 33-0728374 (State or Other Jurisdiction of Incorporation) (C |
|
| August 6, 2024 |
Dynavax Reports Second Quarter 2024 Financial Results and Provides Business Updates Exhibit 99.1 Dynavax Reports Second Quarter 2024 Financial Results and Provides Business Updates • Achieved record quarterly HEPLISAV-B® net product revenue of $70.2 million, growing 24% year-over-year • Reaffirming full year 2024 HEPLISAV-B net product revenue guidance of $265 - $280 million • Initiated dosing in Phase 1/2 trial of novel shingles vaccine program with clinical data expected in 2H |
|
| August 6, 2024 |
As filed with the Securities and Exchange Commission on August 6, 2024 As filed with the Securities and Exchange Commission on August 6, 2024 Registration No. |
|
| August 6, 2024 |
Dynavax Technologies Corporation Exhibit 10.2 Dynavax Technologies Corporation Annual Bonus Plan Purpose and Effective Date Dynavax Technologies Corporation (“Dynavax” or the “Company”) has established this Annual Bonus Plan (the “Bonus Plan”) to align employee performance with annual corporate and individual goals and to reward the achievement of such goals during a performance year. The Bonus Plan will become effective on Janua |
|
| August 6, 2024 |
Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) Dynavax Technologies Corporation (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit Proposed Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock, $0. |
|
| August 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-34207 Dynavax Te |
|
| August 2, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 01, 2024 Dynavax Technologies Corporation (Exact name of Registrant as Specified in Its Charter) Delaware 001-34207 33-0728374 (State or Other Jurisdiction of Incorporation) (C |
|
| May 24, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 23, 2024 Dynavax Technologies Corporation (Exact name of Registrant as Specified in Its Charter) Delaware 001-34207 33-0728374 (State or Other Jurisdiction of Incorporation) (Comm |
|
| May 8, 2024 |
Dynavax Reports First Quarter 2024 Financial Results and Provides Business Updates Exhibit 99.1 Dynavax Reports First Quarter 2024 Financial Results and Provides Business Updates • HEPLISAV-B® vaccine net product revenue grew 10% year-over-year to approximately $48 million in the first quarter of 2024 • Reaffirming full year 2024 HEPLISAV-B net product revenue guidance of $265 - $280 million • Announces U.S. FDA clearance of IND application to initiate Phase 1/2 trial of Z-1018 |
|
| May 8, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 08, 2024 Dynavax Technologies Corporation (Exact name of Registrant as Specified in Its Charter) Delaware 001-34207 33-0728374 (State or Other Jurisdiction of Incorporation) (Comm |
|
| May 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number: 001-34207 Dynavax |
|
| May 8, 2024 |
Sublease, dated March 7, 2024, by and between Company and Metagenomi, Inc Exhibit 10.1 SUBLEASE BASIC SUBLEASE INFORMATION Effective Date: March 7, 2024 Sublandlord: Dynavax Technologies Corporation, a Delaware corporation Sublandlord’s Address For Notice: Dynavax Technologies Corp. Attn: Chief Financial Officer 2100 Powell Street, Suite 720 Emeryville, CA 94608 With a Copy To: Cooley LLP 11951 Freedom Drive, Suite 1400 Reston, Virginia 20190 Attn: John G. Lavoie, Esq. |
|
| April 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e) |
|
| April 11, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6( |
|
| April 11, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a- |
|
| April 1, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 29, 2024 Dynavax Technologies Corporation (Exact name of Registrant as Specified in Its Charter) Delaware 001-34207 33-0728374 (State or Other Jurisdiction of Incorporation) (Co |
|
| March 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 07, 2024 Dynavax Technologies Corporation (Exact name of Registrant as Specified in Its Charter) Delaware 001-34207 33-0728374 (State or Other Jurisdiction of Incorporation) (Co |
|
| February 22, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 22, 2024 Dynavax Technologies Corporation (Exact name of Registrant as Specified in Its Charter) Delaware 001-34207 33-0728374 (State or Other Jurisdiction of Incorporation) |
|
| February 22, 2024 |
Exhibit 99.1 Dynavax Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Full Year 2024 Financial Guidance • HEPLISAV-B® 2023 net product revenue grew 69% year-over-year to $213 million • Achieved market leader status in key segments retail pharmacy and IDNs in 2023 • 2024 HEPLISAV-B net product revenue expected to be $265 - $280 million • Cash position increased to $742 milli |
|
| February 22, 2024 |
Dynavax Technologies Corporation Incentive Compensation Recoupment Policy Exhibit 97.1 Dynavax Technologies Corporation Incentive Compensation Recoupment Policy Effective November 23, 2023 1. Introduction The Board of Directors (the “Board”) of Dynavax Technologies Corporation, a Delaware corporation (the “Company”), has determined, upon the recommendation of the Compensation Committee of the Board (the “Compensation Committee”), that it is in the best interests of the |
|
| February 22, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-34207 Dynavax Technolog |
|
| February 22, 2024 |
Exhibit 21.1 List of Subsidiaries Dynavax GmbH Dynavax India LLP |
|
| February 14, 2024 |
DVAX / Dynavax Technologies Corporation / Deep Track Capital, LP Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 13, 2024 |
DVAX / Dynavax Technologies Corporation / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 1)* Name of issuer: Dynavax Technologies Corp Title of Class of Securities: Common Stock CUSIP Number: 268158201 Date of Event Which Requires Filing of this Statement: December 29, 2023 Check the appropriate box to designate the rule pursuant to which this Schedule is fi |
|
| January 18, 2024 |
DVAX / Dynavax Technologies Corporation / FEDERATED HERMES, INC. Passive Investment OMB APPROVAL OMB Number: 3235-0145 Estimated average burden hours per response ….11 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 23*) DYNAVAX TECHNOLOGIES CORPORATION (Name of Issuer) COMMON STOCK (Title of Class of Securities) 268158201 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Fi |
|
| January 8, 2024 |
Dynavax Announces Preliminary Unaudited Fourth Quarter and Full Year 2023 Financial Highlights Dynavax Announces Preliminary Unaudited Fourth Quarter and Full Year 2023 Financial Highlights • Preliminary full year 2023 HEPLISAV-B® vaccine net product revenue of approximately $213 million, a 69% year-over-year increase • Significant gains in HEPLISAV-B market share in key market segments, with total U. |
|
| January 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 08, 2024 Dynavax Technologies Corporation (Exact name of Registrant as Specified in Its Charter) Delaware 001-34207 33-0728374 (State or Other Jurisdiction of Incorporation) ( |
|
| January 8, 2024 |
Developing and Commercializing Innovative Vaccines 42nd Annual J.P. Morgan Healthcare Conference January 2024 Nasdaq: DVAX Forward-Looking Statements Statements contained in this presentation regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements about Dynavax's expected finan |
|
| November 2, 2023 |
Dynavax Reports Third Quarter 2023 Financial Results and Raises Full Year Revenue Guidance Dynavax Reports Third Quarter 2023 Financial Results and Raises Full Year Revenue Guidance • Generated quarterly HEPLISAV-B® vaccine net product revenue of $62. |
|
| November 2, 2023 |
[*] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential. |
|
| November 2, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number: 001-34207 Dyn |
|
| November 2, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 02, 2023 Dynavax Technologies Corporation (Exact name of Registrant as Specified in Its Charter) Delaware 001-34207 33-0728374 (State or Other Jurisdiction of Incorporation) |
|
| September 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 07, 2023 Dynavax Technologies Corporation (Exact name of Registrant as Specified in Its Charter) Delaware 001-34207 33-0728374 (State or Other Jurisdiction of Incorporation) |
|
| September 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 29, 2023 Dynavax Technologies Corporation (Exact name of Registrant as Specified in Its Charter) Delaware 001-34207 33-0728374 (State or Other Jurisdiction of Incorporation) (C |
|
| August 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 03, 2023 Dynavax Technologies Corporation (Exact name of Registrant as Specified in Its Charter) Delaware 001-34207 33-0728374 (State or Other Jurisdiction of Incorporation) (C |
|
| August 3, 2023 |
Amendment No. 1 to Sales Agreement with Cowen and Company, LLC Exhibit 1.3 AMENDMENT NO. 1 TO SALES AGREEMENT August 3, 2023 Dynavax Technologies Corporation 2100 Powell Street, Suite 720 Emeryville, CA 94608 Ladies and Gentlemen: Dynavax Technologies Corporation, a Delaware corporation (the “Company”), together with Cowen and Company, LLC (the “Agent”), are parties to that certain Sales Agreement dated August 6, 2020 (the “Original Agreement”). All capitaliz |
|
| August 3, 2023 |
Dynavax Reports Second Quarter 2023 Financial Results and Raises Full Year Revenue Guidance Exhibit 99.1 Dynavax Reports Second Quarter 2023 Financial Results and Raises Full Year Revenue Guidance • Generated record quarterly HEPLISAV-B® vaccine net product revenue of $56 million, a 73% year-over-year increase • Full year HEPLISAV-B net product revenue guidance raised to $200 - $215 million, compared to prior range of $165 - $185 million • Cash and investments increased to $682 million a |
|
| August 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number: 001-34207 Dynavax |
|
| August 3, 2023 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Dynavax Technologies Corporation (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward Form Type Carry Forward File Number Carry Forward Initial Effective Date Filing Fee Previously Paid In Connection with Unsold Securities to be Carried Forward Newly Registered Securities Fees to Be Paid Equity Common Stock, par value $0. |
|
| August 3, 2023 |
Form of Debt Indenture, between the Company and one or more trustees to be named EX-4.8 Exhibit 4.8 DYNAVAX TECHNOLOGIES CORPORATION, Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [•], 20 Debt Securities TABLE OF CONTENTS Page ARTICLE 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1 ARTICLE 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 4 Section 2.01 Designation and Terms of Securities 4 Section 2.02 Form of Securities and Trustee’s C |
|
| August 3, 2023 |
Form of Common Stock Warrant Agreement EX-4.3 Exhibit 4.3 DYNAVAX TECHNOLOGIES CORPORATION AND [ ], AS WARRANT AGENT FORM OF COMMON STOCK WARRANT AGREEMENT DATED AS OF [ ] DYNAVAX TECHNOLOGIES CORPORATION FORM OF COMMON STOCK WARRANT AGREEMENT This COMMON STOCK WARRANT AGREEMENT (this “Agreement”), dated as of [ ], between DYNAVAX TECHNOLOGIES CORPORATION, a Delaware corporation (the “Company”) and [ ], a [corporation] [national bankin |
|
| August 3, 2023 |
eXHIBIT 10.3 DYNAVAX TECHNOLOGIES CORPORATION MANAGEMENT CONTINUITY AND SEVERANCE AGREEMENT This Management Continuity and Severance Agreement (the “Agreement”) is dated as of [, 20], by and between [] (“Employee”) and Dynavax Technologies Corporation, a Delaware corporation (the “Company”). RECITALS A. It is expected that another company may from time to time consider the possibility of acquiring |
|
| August 3, 2023 |
[*] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential. |
|
| August 3, 2023 |
Form of Debt Securities Warrant Agreement Exhibit 4.5 DYNAVAX TECHNOLOGIES CORPORATION and [ ], AS WARRANT AGENT FORM OF DEBT SECURITIES WARRANT AGREEMENT DATED AS OF [ ] DYNAVAX TECHNOLOGIES CORPORATION FORM OF DEBT SECURITIES WARRANT AGREEMENT DEBT SECURITIES WARRANT AGREEMENT (this “Agreement”), dated as of [ ], between DYNAVAX TECHNOLOGIES CORPORATION, a Delaware corporation (the “Company”) and, [ ], a [corporation] [national banking |
|
| August 3, 2023 |
[*] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential. |
|
| August 3, 2023 |
Form of Preferred Stock Warrant Agreement EX-4.4 Exhibit 4.4 DYNAVAX TECHNOLOGIES CORPORATION AND [ ], AS WARRANT AGENT FORM OF PREFERRED STOCK WARRANT AGREEMENT DATED AS OF [ ] DVNAVAX TECHNOLOGIES CORPORATION FORM OF PREFERRED STOCK WARRANT AGREEMENT PREFERRED STOCK WARRANT AGREEMENT (this “Agreement”), dated as of [ ] between DYNAVAX TECHNOLOGIES CORPORATION, a Delaware corporation (the “Company”) and [ ], a [corporation] [national ban |
|
| August 3, 2023 |
As filed with the Securities and Exchange Commission on August 3, 2023 S-3ASR Table of Contents As filed with the Securities and Exchange Commission on August 3, 2023 Registration No. |
|
| July 5, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 30, 2023 Dynavax Technologies Corporation (Exact name of Registrant as Specified in Its Charter) Delaware 001-34207 33-0728374 (State or Other Jurisdiction of Incorporation) (Com |
|
| May 26, 2023 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 26, 2023 Dynavax Technologies Corporation (Exact name of Registrant as Specified in Its Charter) Delaware 001-34207 33-0728374 (State or Other Jurisdiction of Incorporation) (Comm |
|
| May 19, 2023 |
DVAX / Dynavax Technologies Corp. / Deep Track Capital, LP Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| May 2, 2023 |
Dynavax Reports First Quarter 2023 Financial Results Exhibit 99.1 Dynavax Reports First Quarter 2023 Financial Results • HEPLISAV-B® vaccine net product revenue increased 109% year-over-year to $43.5 million in the first quarter of 2023 • Reaffirming HEPLISAV-B net product revenue guidance for full year 2023 of between $165–$185 million, representing annual revenue growth of 30-47% • Strengthened balance sheet with cash and investments of $652 milli |
|
| May 2, 2023 |
Consulting Agreement, effective January 16, 2023, between Company and Peter Paradiso Exhibit 10.1 Consulting Agreement This Consulting Agreement (the “Agreement”) is effective on January 16, 2023 (the “Effective Date”), between Dynavax Technologies Corporation, with an address at 2100 Powell Street, Suite 720, Emeryville, CA 94608 (“Dynavax”), and Peter Paradiso, with an address at [address], (“Consultant”). Dynavax and Consultant may be collectively referred to herein as the “Par |
|
| May 2, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 02, 2023 Dynavax Technologies Corporation (Exact name of Registrant as Specified in Its Charter) Delaware 001-34207 33-0728374 (State or Other Jurisdiction of Incorporation) (Comm |
|
| May 2, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number: 001-34207 Dynavax |
|
| April 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a- |
|
| April 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: □ Preliminary Proxy Statement □ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e) |
|
| February 23, 2023 |
Supply Agreement, dated effective April 1, 2021, between Company and Becton, Dickinson and Company EXECUTION VERSION [*] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential. |
|
| February 23, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 23, 2023 Dynavax Technologies Corporation (Exact name of Registrant as Specified in Its Charter) Delaware 001-34207 33-0728374 (State or Other Jurisdiction of Incorporation) |
|
| February 23, 2023 |
Exhibit 99.1 Dynavax Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Full Year 2023 Financial Guidance • 2022 total revenue of $723 million, up 64% from $439 million in 2021 o HEPLISAV-B® vaccine net product revenue of $126 million, representing 104% growth compared to 2021 o CpG 1018® adjuvant vaccine net product revenue of $588 million • 2023 HEPLISAV-B net product reven |
|
| February 23, 2023 |
[*] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential. |
|
| February 23, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-34207 Dynavax Technolog |
|
| February 23, 2023 |
Exhibit 21.1 List of Subsidiaries Dynavax GmbH Dynavax India LLP |
|
| February 23, 2023 |
[*] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential. |
|
| February 23, 2023 |
[*] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential. |
|
| February 9, 2023 |
DVAX / Dynavax Technologies Corporation / VANGUARD GROUP INC - SCHEDULE 13G Passive Investment SC 13G 1 tv0776-dynavaxtechnologiesco.htm SCHEDULE 13G SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 Name of issuer: Dynavax Technologies Corp. Title of Class of Securities: Common Stock CUSIP Number: 268158201 Date of Event Which Requires Filing of this Statement: December 30, 2022 Check the appropriate box to designate the rule p |
|
| February 1, 2023 |
DVAX / Dynavax Technologies Corporation / FEDERATED HERMES, INC. Passive Investment SC 13G/A 1 form821.htm OMB APPROVAL OMB Number: 3235-0145 Estimated average burden hours per response ….11 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 22*) DYNAVAX TECHNOLOGIES CORPORATION (Name of Issuer) COMMON STOCK (Title of Class of Securities) 268158201 (CUSIP Number) December 31, 2022 (Date of |
|
| January 9, 2023 |
Developing and Commercializing Innovative Vaccines Using Proven, Innovative Adjuvant Technology to Help Protect the World Against Infectious Diseases January 2023 Nasdaq: DVAX Exhibit 99. |
|
| January 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 09, 2023 Dynavax Technologies Corporation (Exact name of Registrant as Specified in Its Charter) Delaware 001-34207 33-0728374 (State or Other Jurisdiction of Incorporation) ( |
|
| January 9, 2023 |
EX-99.1 2 dvax-ex991.htm EX-99.1 Exhibit 99.1 Dynavax Announces Preliminary Unaudited Fourth Quarter and Full Year 2022 Financial Highlights and Phase 1 Shingles Topline Results • Preliminary full year 2022 HEPLISAV-B® vaccine Net Product Revenue of approximately $126 million, representing 104% growth compared to 2021 • Preliminary full year CpG 1018® adjuvant Net Product Revenue of approximately |
|
| November 3, 2022 |
[*] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential. |
|
| November 3, 2022 |
[*] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential. |
|
| November 3, 2022 |
[*] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential. |
|
| November 3, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number: 001-34207 Dyn |
|
| November 3, 2022 |
[*] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential. |
|
| November 3, 2022 |
Dynavax Reports Third Quarter 2022 Financial Results Exhibit 99.1 Dynavax Reports Third Quarter 2022 Financial Results • Q3 2022 total revenue of $167.7 million, up 55% from $108.3 million for Q3 2021 o HEPLISAV-B® vaccine net product revenue of $37.5 million, up 65% from $22.7 million for Q3 2021 o CpG 1018® adjuvant net product revenue of $126.3 million, up 50% from $84.3 million for Q3 2021 • Reiterates guidance for full-year CpG 1018 adjuvant ne |
|
| November 3, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 03, 2022 Dynavax Technologies Corporation (Exact name of Registrant as Specified in Its Charter) Delaware 001-34207 33-0728374 (State or Other Jurisdiction of Incorporation) |
|
| August 17, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13D (Rule 13d-101) Information to be Included in Statements Filed Pursuant to ? 240. |
|
| August 4, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number: 001-34207 Dynavax |
|
| August 4, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 04, 2022 Dynavax Technologies Corporation (Exact name of Registrant as Specified in Its Charter) Delaware 001-34207 33-0728374 (State or Other Jurisdiction of Incorporation) (C |
|
| August 4, 2022 |
Dynavax Reports Second Quarter 2022 Financial Results Exhibit 99.1 Dynavax Reports Second Quarter 2022 Financial Results ? Q2 2022 total revenue of $256.5 million, up 386% from $52.8 million for Q2 2021 o HEPLISAV-B? vaccine net product revenue of $32.7 million, up 139% from $13.7 million for Q2 2021 o CpG 1018? adjuvant net product revenue of $222.6 million, up 471% from $39.0 million for Q2 2021 ? On track for second consecutive year of profitabili |
|
| June 2, 2022 |
Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) Dynavax Technologies Corporation (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit Proposed Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock, $0. |
|
| June 2, 2022 |
As filed with the Securities and Exchange Commission on June 2, 2022 As filed with the Securities and Exchange Commission on June 2, 2022 Registration No. |
|
| May 26, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 26, 2022 Dynavax Technologies Corporation (Exact name of Registrant as Specified in Its Charter) Delaware 001-34207 33-0728374 (State or Other Jurisdiction of Incorporation) (Comm |
|
| May 5, 2022 |
Lease Agreement, dated March 15, 2022, by and between Company and SPUS8 2100 Powell, L.P. Exhibit 10.1 OFFICE LEASE by and between SPUS8 2100 POWELL, LP, a Delaware limited partnership, as Landlord and DYNAVAX TECHNOLOGIES CORPORATION, a Delaware corporation, as Tenant, Premises: 2100 Powell Street Suite 720 Emeryville, California 94608 TABLE OF CONTENTS ARTICLE 1 BASIC LEASE PROVISIONS 1 ARTICLE 2 DEMISE; USE; AND TERM 3 ARTICLE 3 RENT; OPERATING EXPENSES; TAXES; AND ELECTRICITY 4 ART |
|
| May 5, 2022 |
Dynavax Reports First Quarter 2022 Financial Results Exhibit 99.1 Dynavax Reports First Quarter 2022 Financial Results ? First quarter 2022 total revenue of $114.0 million, up 37% from $83.3 million for Q1 2021 o HEPLISAV-B? vaccine net product revenue of $20.8 million, up 151% from $8.3 million for Q1 2021 o CpG 1018? adjuvant net product revenue of $91.5 million, up 23% from $74.6 million for Q1 2021 ? Guidance reiterated for 2022 CpG 1018 revenue |
|
| May 5, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 05, 2022 Dynavax Technologies Corporation (Exact name of Registrant as Specified in Its Charter) Delaware 001-34207 33-0728374 (State or Other Jurisdiction of Incorporation) (Comm |
|
| May 5, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number: 001-34207 Dynavax |
|
| April 14, 2022 |
Amended and Restated Dynavax Technologies Corporation 2018 Equity Incentive Plan UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.??) Filed by the Registrant ? ? ? Filed by a Party other than the Registrant ?? Check the appropriate box: ?? Preliminary Proxy Statement ?? Confidential, for Use of the Commission Only (as permitted by Rule |
|
| April 14, 2022 |
DEFA14A 1 ny20002052x2defa14a.htm FORM DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of |
|
| March 16, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 15, 2022 Dynavax Technologies Corporation (Exact name of Registrant as Specified in Its Charter) Delaware 001-34207 33-0728374 (State or Other Jurisdiction of Incorporation) (Co |
|
| February 28, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 28, 2022 Dynavax Technologies Corporation (Exact name of Registrant as Specified in Its Charter) Delaware 001-34207 33-0728374 (State or Other Jurisdiction of Incorporation) |
|
| February 28, 2022 |
Non-Employee Director Compensation Policy Exhibit 10.34 DYNAVAX TECHNOLOGIES CORPORATION NON-EMPLOYEE DIRECTOR COMPENSATION POLICY EFFECTIVE OCTOBER 2021 Directors who are not Employees (?Non-Employee Directors?) shall receive equity and cash compensation as set forth below. Capitalized terms used in this Policy, unless otherwise defined herein, have the meaning given to them in the Company?s Amended and Restated 2018 Equity Incentive Pla |
|
| February 28, 2022 |
Exhibit 10.21 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED. From: Valneva Scotland Limited (?Purchaser?) Oakbank Park Road, Livingston, Scotland EH53 0TG, United Kingdom And: Valneva Austria GmbH (?Valneva Austria?) Campus Vienna Biocenter 3 1030 |
|
| February 28, 2022 |
Exhibit 4.1 DESCRIPTION OF CAPITAL STOCK References herein to ?Dynavax,? ?our,? ?we,? ?us? and the ?Company? refer only to Dynavax Technologies Corporation. General Our authorized capital stock consists of 278,000,000 shares of common stock, $0.001 par value per share, and 5,000,000 shares of preferred stock, $0.001 par value per share. Our common stock is the only security of the Company register |
|
| February 28, 2022 |
Exhibit 21.1 List of Subsidiaries Dynavax GmbH Dynavax India LLP |
|
| February 28, 2022 |
Exhibit 99.1 Dynavax Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Full Year 2022 Financial Guidance ? Record 2021 total revenue of $439 million, up from $47 million for 2020 o Record full year HEPLISAV-B? net product revenue of $62 million o Record full year CpG 1018? adjuvant net product revenue of $375 million, meeting previously announced 2021 guidance ? 2021 GAAP Ne |
|
| February 28, 2022 |
Restricted Stock Unit Award Agreement for Directors under the 2018 Equity Incentive Plan Exhibit 10.11 Dynavax Technologies Corporation 2018 Equity Incentive Plan Restricted Stock Unit Award Agreement Pursuant to the accompanying Restricted Stock Unit Award Grant Notice (the ?Grant Notice?) and this Restricted Stock Unit Award Agreement (the ?Agreement?), Dynavax Technologies Corporation (the ?Company?) has granted you a Restricted Stock Unit Award (the ?Award?) under the Dynavax Tech |
|
| February 28, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-34207 Dynavax Technolog |
|
| February 14, 2022 |
DVAX / Dynavax Technologies Corporation / FEDERATED HERMES, INC. Passive Investment SC 13G/A 1 dvax57.htm OMB APPROVAL OMB Number: 3235-0145 Estimated average burden hours per response ….11 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 21*) DYNAVAX TECHNOLOGIES CORPORATION (Name of Issuer) COMMON STOCK (Title of Class of Securities) 268158201 (CUSIP Number) December 31, 2021 (Date of E |
|
| December 14, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 10, 2021 Dynavax Technologies Corporation (Exact name of Registrant as Specified in Its Charter) Delaware 001-34207 33-0728374 (State or Other Jurisdiction of Incorporation) |
|
| November 4, 2021 |
Dynavax Reports Third Quarter 2021 Financial Results Exhibit 99.1 Dynavax Reports Third Quarter 2021 Financial Results ? Third quarter 2021 total revenue of $108.3 million o HEPLISAV-B net product revenue of $22.7 million o CpG 1018? adjuvant product revenue of $84.3 million ? Increased 2021 full-year CpG 1018 revenue guidance to be between $375 and $425 million ? ACIP voted unanimously to recommend that all adults 19 to 59 years of age should recei |
|
| November 4, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number: 001-34207 Dyn |
|
| November 4, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 04, 2021 Dynavax Technologies Corporation (Exact name of Registrant as Specified in Its Charter) Delaware 001-34207 33-0728374 (State or Other Jurisdiction of Incorporation) |
|
| November 4, 2021 |
Exhibit 10.2 COMMERCIAL LEASE between Onyx D?sseldorf S.? r.l. 2-4, Rue Eug?ne Ruppert 2453 Luxembourg Luxembourg, a limited liability company (soci?t? ? responsabilit? limit?e) established and existing under the laws of the Grand Duchy of Luxembourg and registered with the Commercial Register of Luxembourg (registre de commerce et des soci?t?s) under RCS No. 111201, represented by its sole managi |
|
| November 4, 2021 |
Exhibit 10.3 FIRST AMENDMENT TO COMMERCIAL MANUFACTURING AND SUPPLY AGREEMENT THIS FIRST AMENDMENT TO COMMERCIAL MANUFACTURING AND SUPPLY AGREEMENT (?First Amendment?) is entered into as of the 10th day of September, 2021 (?First Amendment Effective Date?), by and between BAXTER PHARMACEUTICAL SOLUTIONS LLC, a Delaware limited liability company having a place of business at 927 South Curry Pike, B |
|
| October 21, 2021 |
DYNAVAX TECHNOLOGIES CORPORATION NON-EMPLOYEE DIRECTOR COMPENSATION POLICY EFFECTIVE OCTOBER 2021 Exhibit 99.1 DYNAVAX TECHNOLOGIES CORPORATION NON-EMPLOYEE DIRECTOR COMPENSATION POLICY EFFECTIVE OCTOBER 2021 Directors who are not Employees (?Non-Employee Directors?) shall receive equity and cash compensation as set forth below. Capitalized terms used in this Policy, unless otherwise defined herein, have the meaning given to them in the Company?s Amended and Restated 2018 Equity Incentive Plan |
|
| October 21, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 19, 2021 Dynavax Technologies Corporation (Exact name of registrant as specified in its charter) Commission File Number: 001-34207 Delaware 33-0728374 (State or other jurisdic |
|
| August 27, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13D (Rule 13d-101) Information to be Included in Statements Filed Pursuant to ? 240. |
|
| August 11, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13D (Rule 13d-101) Information to be Included in Statements Filed Pursuant to ? 240. |
|
| August 4, 2021 |
Supply Agreement, dated July 1, 2021, by and between Company and Biological E. Limited Exhibit 10.7 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED. Supply Agreement Supply Agreement Summary CUSTOMER INFORMATION Name: Biological E. Limited (?Customer?) Mailing Address: 18/1&3, Azamabad Hyderabad-500020, Telangana India Designated Cont |
|
| August 4, 2021 |
Exhibit 10.6 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED. Supply Agreement Supply Agreement Summary CUSTOMER INFORMATION Name: Zhejiang Clover Biopharmaceuticals, Inc., a company organized under the laws of P.R. China (?Zhejiang Clover?), and Cl |
|
| August 4, 2021 |
As filed with the Securities and Exchange Commission on August 4, 2021 As filed with the Securities and Exchange Commission on August 4, 2021 Registration No. |
|
| August 4, 2021 |
Exhibit 10.2 AMENDMENT NO. 5 TO TERM LOAN AGREEMENT THIS AMENDMENT NO. 5 TO TERM LOAN AGREEMENT, dated as of [May 1], 2021 (this ?Agreement?), is made among Dynavax Technologies Corporation, a Delaware corporation (the ?Borrower?), the Subsidiary Guarantors party hereto, the Lenders party hereto and CRG Servicing LLC, as administrative agent and collateral agent (in such capacities, ?Agent?), with |
|
| August 4, 2021 |
Exhibit 10.1 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED. First Amendment to Agreement This First Amendment to Agreement (?First Amendment?) is entered into as of the date of last signature by and between Coalition for Epidemic Preparedness Inno |
|
| August 4, 2021 |
Amended and Restated Dynavax Technologies Corporation 2021 Inducement Award Plan Exhibit 10.3 Dynavax Technologies Corporation 2021 Inducement Award Plan Adopted by the Compensation Committee: January 9, 2021 Amended and Restated by the Compensation Committee: June 22, 2021 1 General. (a)Eligible Award Recipients. Awards may only be granted to Employees who satisfy the standards for inducement grants under Rule 5635(c)(4) of the Nasdaq Listing Rules. A person who previously se |
|
| August 4, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number: 001-34207 Dynavax |
|
| August 4, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 4, 2021 Dynavax Technologies Corporation (Exact name of registrant as specified in its charter) Commission File Number: 001-34207 Delaware 33-0728374 (State or other jurisdicti |
|
| August 4, 2021 |
Dynavax Announces Second Quarter 2021 Financial Results Exhibit 99.1 Dynavax Announces Second Quarter 2021 Financial Results ? Second quarter 2021 total revenue of $52.8 million, which includes HEPLISAV-B?s highest quarterly revenue to date at $13.7 million ? Executed multiple commercial supply agreements for CpG 1018? adjuvant with our COVID-19 vaccine collaborators ? Conference call to be held today at 4:30 p.m. ET/1:30 p.m. PT EMERYVILLE, CA ? Augus |
|
| July 7, 2021 |
Entry into a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 1, 2021 Dynavax Technologies Corporation (Exact name of registrant as specified in its charter) Commission File Number: 001-34207 Delaware 33-0728374 (State or other jurisdiction |
|
| July 1, 2021 |
Entry into a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 29, 2021 Dynavax Technologies Corporation (Exact name of registrant as specified in its charter) Commission File Number: 001-34207 Delaware 33-0728374 (State or other jurisdictio |
|
| June 24, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 22, 2021 Dynavax Technologies Corporation (Exact name of registrant as specified in its charter) Commission File Number: 001-34207 Delaware 33-0728374 (State or other jurisdictio |
|
| June 11, 2021 |
SC 13D/A 1 d160895dsc13da.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13D (Rule 13d-101) Information to be Included in Statements Filed Pursuant to § 240.13d-1(a) and Amendments Thereto Filed Pursuant to § 240.13d-2(a) Under the Securities Exchange Act of 1934 (Amendment No. 3) Dynavax Technologies Corporation (Name of Issuer) Common Stock, $0.001 pa |
|
| June 2, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 28, 2021 Dynavax Technologies Corporation (Exact name of registrant as specified in its charter) Commission File Number: 001-34207 Delaware 33-0728374 (State or other jurisdiction |
|
| May 26, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 25, 2021 Dynavax Technologies Corporation (Exact name of registrant as specified in its charter) Commission File Number: 001-34207 Delaware 33-0728374 (State or other jurisdiction |
|
| May 13, 2021 |
EX-4.1 2 d481425dex41.htm EX-4.1 Exhibit 4.1 DYNAVAX TECHNOLOGIES CORPORATION AND U.S. BANK NATIONAL ASSOCIATION, as Trustee INDENTURE Dated as of May 13, 2021 2.50% Convertible Senior Notes due 2026 TABLE OF CONTENTS PAGE ARTICLE 1 DEFINITIONS Section 1.01. Definitions 1 Section 1.02. References to Interest 15 ARTICLE 2 ISSUE, DESCRIPTION, EXECUTION, REGISTRATION AND EXCHANGE OF NOTES Section 2.0 |
|
| May 13, 2021 |
Form of Confirmation for Capped Call Transactions Exhibit 10.1 [] [Dealer name and address] To: [Counterparty] [] [] [] From: [Dealer] Re: [Base][Additional] Capped Call Transaction Ref. No: []1 Date: May [ ], 2021 Dear Ladies and Gentlemen: The purpose of this communication (this ?Confirmation?) is to set forth the terms and conditions of the above-referenced transaction entered into on the Trade Date specified below (the ?Transaction?) between |
|
| May 13, 2021 |
Dynavax Announces Pricing of $200 Million Convertible Senior Notes Offering EX-99.2 5 d481425dex992.htm EX-99.2 Exhibit 99.2 Dynavax Announces Pricing of $200 Million Convertible Senior Notes Offering EMERYVILLE, Calif., May 11, 2021 — Dynavax Technologies Corporation (“Dynavax”) (Nasdaq: DVAX) today announced the pricing of $200.0 million aggregate principal amount of 2.50% convertible senior notes due 2026 (the “notes”) in a private placement to persons reasonably belie |
|
| May 13, 2021 |
Dynavax Announces Proposed Private Offering of $200 Million of Convertible Senior Notes Exhibit 99.1 Dynavax Announces Proposed Private Offering of $200 Million of Convertible Senior Notes EMERYVILLE, Calif., May 10, 2021 ? Dynavax Technologies Corporation (?Dynavax?) (Nasdaq: DVAX) today announced that it intends to offer, subject to market conditions and other factors, $200 million aggregate principal amount of convertible senior notes due 2026 (the ?notes?) in a private placement |
|
| May 13, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 10, 2021 Dynavax Technologies Corporation (Exact name of registrant as specified in its charter) Commission File Number: 001-34207 Delaware 33-0728374 (State or other jurisdiction |
|
| May 6, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 6, 2021 Dynavax Technologies Corporation (Exact name of registrant as specified in its charter) Commission File Number: 001-34207 Delaware 33-0728374 (State or other jurisdiction |
|
| May 6, 2021 |
Dynavax Announces First Quarter 2021 Financial Results Exhibit 99.1 Dynavax Announces First Quarter 2021 Financial Results ▪ First quarter 2021 total revenue of $83.3 million, driven by strong execution in the CpG 1018 adjuvant business ▪ Conference call to be held today at 4:30 p.m. ET/1:30 p.m. PT EMERYVILLE, CA – May 6, 2021 – Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing nove |
|
| May 6, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number: 001-34207 Dynavax |
|
| May 5, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 3, 2021 Dynavax Technologies Corporation (Exact name of registrant as specified in its charter) Commission File Number: 001-34207 Delaware 33-0728374 (State or other jurisdiction |
|
| April 16, 2021 |
Dynavax Technologies Corporation Amended and Restated 2014 Employee Stock Purchase Plan UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.??) Filed by the Registrant ? ? ? Filed by a Party other than the Registrant ?? Check the appropriate box: ?? Preliminary Proxy Statement ?? Confidential, for Use of the Commission Only (as permitted by Rule |
|
| April 16, 2021 |
DEFA14A 1 nc10020263x2defa14a.htm DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the C |
|
| April 6, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 6, 2021 Dynavax Technologies Corporation (Exact name of registrant as specified in its charter) Commission File Number: 001-34207 Delaware 33-0728374 (State or other jurisdictio |
|
| February 25, 2021 |
EX-10.31 3 dvax-ex1031356.htm EX-10.31 Exhibit 10.31 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED. Agreement This Agreement (“Agreement”) is entered into as of the date of last signature by and between Coalition for Epidemic Preparedness Innovati |
|
| February 25, 2021 |
Exhibit 10.32 AMENDMENT NO. 4 TO TERM LOAN AGREEMENT THIS AMENDMENT NO. 4 TO TERM LOAN AGREEMENT, dated as of January 28, 2021 (this ?Agreement?), is made among Dynavax Technologies Corporation, a Delaware corporation (the ?Borrower?), the Subsidiary Guarantors party hereto, the Lenders party hereto and CRG Servicing LLC, as administrative agent and collateral agent (in such capacities, ?Agent?), |
|
| February 25, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 25, 2021 Dynavax Technologies Corporation (Exact name of registrant as specified in its charter) Commission File Number: 001-34207 Delaware 33-0728374 (State or other jurisdi |
|
| February 25, 2021 |
Offer Letter, dated December 14, 2020, by and between Company and Kelly MacDonald Exhibit 10.33 December 14, 2020 Kelly MacDonald Subject: Offer Letter Dear Kelly: Dynavax Technologies is pleased to offer you the position of Senior Vice President, Chief Financial Officer, on the terms outlined below. We are excited that you will be joining our team of dedicated and talented professionals focused on investigating, developing and commercializing innovative vaccines to provide pro |
|
| February 25, 2021 |
Dynavax Announces Fourth Quarter and Full Year 2020 Financial Results Exhibit 99.1 Dynavax Announces Fourth Quarter and Full Year 2020 Financial Results ▪ Substantial progress in 2020 on both HEPLISAV-B and CpG 1018 businesses ▪ Full year 2020 total revenue of $46.6 million, an increase of 32% from 2019 total revenue of $35.2 million ▪ First quarter 2021 CpG 1018 revenue anticipated to be between $40 million and $60 million ▪ Conference call to be held today at 4:30 |
|
| February 25, 2021 |
As filed with the U.S. Securities and Exchange Commission on February 25, 2021 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 DYNAVAX TECHNOLOGIES CORPORATION (Exact Name of Registrant as Specified in its Charter) Delaware 33-0728374 (State or other jurisdiction of incorporation or organ |
|
| February 25, 2021 |
EX-21.1 6 dvax-ex21115.htm EX-21.1 Exhibit 21.1 List of Subsidiaries Dynavax GmbH Dynavax India LLP |
|
| February 25, 2021 |
Exhibit 4.1 DESCRIPTION OF CAPITAL STOCK References herein to “Dynavax,” “our,” “we,” “us” and the “Company” refer only to Dynavax Technologies Corporation. General Our authorized capital stock consists of 278,000,000 shares of common stock, $0.001 par value per share, and 5,000,000 shares of preferred stock, $0.001 par value per share, 4,840 shares of which have been designated as Series B Conver |
|
| February 25, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-34207 Dynavax Technolog |
|
| February 19, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 19, 2021 Dynavax Technologies Corporation (Exact name of registrant as specified in its charter) Commission File Number: 001-34207 Delaware 33-0728374 (State or other jurisdi |
|
| February 19, 2021 |
EX-99.1 2 dvax-ex9916.htm EX-99.1 Exhibit 99.1 Dynavax Announces European Commission Marketing Authorization for HEPLISAV B®, a 2 Dose Adult Hepatitis B Adjuvanted Vaccine • Approval follows positive opinion by European Committee for Medicinal Products for Human Use • Approval based on safety and immunogenicity results from three Phase 3 clinical trials • Statistically significantly higher and fas |
|
| February 12, 2021 |
OMB APPROVAL OMB Number: 3235-0145 Estimated average burden hours per response ….11 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 20*) DYNAVAX TECHNOLOGIES CORPORATION (Name of Issuer) COMMON STOCK (Title of Class of Securities) 268158201 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Fi |
|
| February 1, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 29, 2021 Dynavax Technologies Corporation (Exact name of registrant as specified in its charter) Commission File Number: 001-34207 Delaware 33-0728374 (State or other jurisdic |
|
| January 21, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 19, 2021 Dynavax Technologies Corporation (Exact name of registrant as specified in its charter) Commission File Number: 001-34207 Delaware 33-0728374 (State or other jurisdic |
|
| January 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 9, 2021 Dynavax Technologies Corporation (Exact name of registrant as specified in its charter) Commission File Number: 001-34207 Delaware 33-0728374 (State or other jurisdict |
|
| January 12, 2021 |
EX-10.1 2 dvax-ex1016.htm EX-10.1 Exhibit 10.1 Dynavax Technologies Corporation 2021 Inducement Award Plan Adopted by the Compensation Committee: January 9, 2021 1.General. (a)Eligible Award Recipients. Awards may only be granted to Employees who satisfy the standards for inducement grants under Rule 5635(c)(4) of the Nasdaq Listing Rules. A person who previously served as an Employee or Director |
|
| January 7, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 7, 2021 Dynavax Technologies Corporation (Exact name of registrant as specified in its charter) Commission File Number: 001-34207 Delaware 33-0728374 (State or other jurisdict |
|
| November 5, 2020 |
Exhibit 10.4 AMENDMENT NO. 3 TO TERM LOAN AGREEMENT THIS AMENDMENT NO. 3 TO TERM LOAN AGREEMENT, dated as of November 2, 2020 (this “Agreement”), is made among Dynavax Technologies Corporation, a Delaware corporation (the “Borrower”), the Subsidiary Guarantors party hereto, the Lenders party hereto and CRG Servicing LLC, as administrative agent and collateral agent (in such capacities, “Agent”), w |
|
| November 5, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number: 001-34207 Dyn |
|
| November 5, 2020 |
Exhibit 10.3 DYNAVAX TECHNOLOGIES CORPORATION Amended and Restated MANAGEMENT CONTINUITY AND SEVERANCE AGREEMENT This Amended and Restated Management Continuity and Severance Agreement (the “Agreement”) is dated as of September 22, 2020, by and between Michael S. Ostrach (“Employee”) and Dynavax Technologies Corporation, a Delaware corporation (the “Company”). RECITALS A.It is expected that anothe |
|
| November 5, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 5, 2020 Dynavax Technologies Corporation (Exact name of registrant as specified in its charter) Commission File Number: 001-34207 Delaware 33-0728374 (State or other jurisdic |
|
| November 5, 2020 |
Exhibit 10.2 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED. CONFIDENTIAL SUPPLY AGREEMENT This Supply Agreement (the “Agreement”), which shall become effective in accordance with Section 10.1, is entered into by and between Dynavax Technologies Co |
|
| November 5, 2020 |
Dynavax Announces Third Quarter 2020 Financial Results EX-99.1 2 dvax-ex99115.htm EX-99.1 Exhibit 99.1 Dynavax Announces Third Quarter 2020 Financial Results ▪ Third quarter 2020 HEPLISAV-B® net product revenue highest since launch at $11.6 million, despite impact of COVID-19 ▪ Initial CpG 1018 revenue and deferred revenue totaling $23.4 million in third quarter, with potential 2021 revenue between approximately $130 to $230 million ▪ Conference call |
|
| September 24, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 22, 2020 Dynavax Technologies Corporation (Exact name of registrant as specified in its charter) Commission File Number: 001-34207 Delaware 33-0728374 (State or other jurisd |
